CD274 and nonpapillary renal cell carcinoma: The first prospective trial in this setting assessed the soluble VEGF-targeted mAb bevacizumab, in combination with the anti PD-L1–targeted mAb atezolizumab, among patients with nccRCC, but it also included patients with ccRCC with sarcomatoid features.